Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sequential pulsed teriflunomide + decitabine + lisaftoclax in TP53 multi-hit myelodysplastic neoplasms
ChiCTR2600133952Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teriflunomide, decitabine and lisaftoclax in myelodysplastic syndrome (MDS), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Objective response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
teriflunomidedecitabinelisaftoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2600133952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133952.